Trial Profile

2015-12: a Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance with Anti-CD38 (protein) Monoclonal Antibody to Improve Progression Free Survival in Patients with Newly Diagnosed Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Lenalidomide; Melphalan; Thalidomide
Indications Multiple myeloma
Focus Therapeutic Use

15 Sep 2026 Planned End Date changed from 1 Oct 2027 to 1 Oct 2028.
15 Sep 2026 Planned primary completion date changed from 1 Oct 2026 to 1 Oct 2027.
10 Sep 2025 Planned End Date changed from 1 Oct 2026 to 1 Oct 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com